SAFETY AND EFFICACY OF IMPRIME PGG PLUS CETUXIMAB WITH IRINOTECAN AND WITHOUT IRINOTECAN IN PATIENTS WITH ADVANCED COLORECTAL CANCER (CRC): A PHASE 1B/2 STUDY WITH KRAS SUBPOPULATION ANALYSIS

被引：0
|
作者：
Tamayo, M. [1 ]
Cornelio, G. [2 ]
Bautista, J. [1 ]
Flores, M. [2 ]
Tioleco, P. [2 ]
Kurman, M. [3 ]
Vasilakos, J. [4 ]
Marsh, L. [4 ]
Gargano, M. [4 ]
Patchen, M. [4 ]
机构：
[1] Med City, Manila, Philippines
[2] Philippine Gen Hosp, Manila, Philippines
[3] Michael Kurman Consulting, Upper Saddle River, NJ USA
[4] Biothera, Eagan, MN USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [1] A phase Ib/2, dose-escalating, safety, and efficacy study of imprime PGG, cetuximab and irinotecan in patients with advanced colorectal cancer (CRC)
    Tamayo, M. E.
    Cornelio, G. H.
    Bautista, J. B.
    Flores, M. L.
    Kurman, M. R.
    Paul, M. M.
    Gargano, M. A.
    Patchen, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] SAFETY, PHARMACOKINETICS (PK), AND EFFICACY OF IMPRIME PGG PLUS CETUXIMAB (CETUX) WITH AND WITHOUT IRINOTECAN (IRINO) IN ADVANCED METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Tamayo, M. B.
    Cornelio, G. H.
    Bautista, J. B.
    Flores, M. L.
    Tioleco, P. S.
    Vasilakos, J. P.
    Marsh, L. M.
    Walsh, R. M.
    Gargano, M. A.
    Patchen, M. L.
    ANNALS OF ONCOLOGY, 2010, 21 : 195 - 195
  • [3] A phase Ib/II, dose-escalating, safety, and efficacy study of imprime PGG and cetuximab in patients with advanced colorectal cancer (CRC).
    Tamayo, M. B.
    Cornelio, G. H.
    Bautista, J. B.
    Flores, M. L.
    Tioleco, P. S.
    Kurman, M. R.
    Marsh, L. M.
    Gargano, M. A.
    Patchen, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC)
    Shergill, Ardaman
    Liao, Chih-Yi
    Kindler, Hedy L.
    Polite, Blase N.
    Catenacci, Daniel V. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] PHASE II STUDY OF IRINOTECAN PLUS CETUXIMAB FOR PRETREATED METASTATIC COLORECTAL CANCER WITH KRAS WILD TYPE
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Utsunomiya, Setsuo
    Muro, Kei
    ANNALS OF ONCOLOGY, 2010, 21 : 13 - 13
  • [6] The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients
    Sohn, Byeong Seok
    Kim, Tae Won
    Lee, Jae-Lyun
    Ryu, Min-Hee
    Chang, Heung Moon
    Kang, Yoon-Koo
    Park, Hyo Suk
    Na, Young-Soon
    Jang, Se Jin
    Kim, Jin Cheon
    Lee, Jung Shin
    ONCOLOGY, 2009, 77 (3-4) : 224 - 230
  • [7] Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.
    Hong, David S.
    Morris, Van Karlyle
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina Anne
    Kee, Bryan K.
    Zinner, Ralph
    Fogelman, David R.
    Mistry, Reena
    Shureiqi, Imad
    Meric-Bernstam, Funda
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] EFFICACY AND SAFETY OF CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-REFRACTORY ELDERLY PATIENTS (>65 YEARS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 195 - 195
  • [9] Efficacy and safety of Cetuximab plus irinotecan in irinotecan-refractory elderly patients (>65 years) with metastatic colorectal cancer (mCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ONKOLOGIE, 2010, 33 : 174 - 174
  • [10] Phase II study of S-1 in combination with irinotecan in patients with advanced colorectal cancer (CRC)
    Komatsu, Y
    Yuuki, S
    Amano, T
    Machida, N
    Ozasa, M
    Kato, T
    Furukawa, S
    Akita, H
    Asaka, M
    Sakata, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 297S - 297S
12345